Budget impact of everolimus in treating metastatic renal cell carcinoma

American Journal of Pharmacy Benefits

Volumn 4, Issue 6, 2012, Pages

  Lopes, Maria ^a   Chulikavit, Maruit ^b   Parikh, Rohan ^b   Stern, Lee ^b   Liu, Zhimei ^c   Rogerio, Jaqueline ^c  

^a AMC Health   (United States)

^b Analytica International   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; HISTAMINE H1 RECEPTOR ANTAGONIST; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; KIDNEY CARCINOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PREVALENCE; TABLET FORMULATION; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 84869786445     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
2. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115(1):61-67.
3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331-1334.
4. Ljungberg B, Hanbury DC, Kuczyk MA, et al; European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502-1510.
5. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865-875.
6. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193-205.
7. Lang K, Danchenko N, Gondek K, Schwartz B, Thompson D. The burden of illness associated with renal cell carcinoma in the United States. Urol Oncol. 2007;25(5):368-375.
8. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma [published correction appears in N Engl J Med. 2007;357(2):203]. N Engl J Med. 2007;356(2):125-134.
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in meta-static renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.
10. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Palliative Care. Fort Washington, PA: NCCN; 2008:1-49.
11. Afinitor (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2009. http://www.afi nitor.com/advanced-re-nal-cell-carcinoma/hcp/full-prescribing-information.jsp. Accessed May 27, 2011.
12. Motzer RJ, Escudier B, Oudard S, et al; RECORD 1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: fi nal results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
13. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95.
14. Hess G P, Chen CC, Liu ZM, Hill JW, Gesme DH, Agarwala SS. Metastatic renal cell carcinoma: patient characteristics and recent treatment patterns in real-world practice. Paper presented at: AMCP's 23rd Annual Meeting & Showcase; April 27-29, 2011; Minneapolis, MN.
15. Proleukin (aldesleukin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; revised December 2011. http://www.proleukin. com/assets/proleukin.pdf. Accessed May 27, 2011.
16. Sutent (sunitinib) [prescribing information]. New York, NY: Pfi zer Inc; revised April 2012. http://www.pfi zer.com/fi les/products/uspi_sutent.pdf. Accessed May 27, 2011.
17. Torisel (temsirolimus) [prescribing information]. http://www.torisel.com/ Prescribing-Information.aspx. Philadelphia, PA: Wyeth Pharmaceuticals Inc; revised May 2012. Accessed May 27, 2011.
18. Nexavar (sorafenib) [prescribing information]. http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Wayne, NJ: Bayer HealthCare Pharmaceuticals Corporation; revised October 2011. Accessed May 27, 2011.
19. Votrient (pazopanib) [prescribing information]. https://www.gsksource.com/ gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=12795 63278373&featureKey=601903#nlmhighlights. Research Triangle Park, NC: GlaxoSmithKline; revised April 2012. Accessed May 27, 2011.
20. Avastin (bevacizumab) [prescribing information]. http://www.gene.com/gene/ products/information/pdf/avastin-prescribing.pdf. South San Francisco, CA: Genentech Inc; revised April 2012. Accessed May 27, 2011.
21. Physicians' Fee and Coding Guide 2010. 21st ed. Atlanta, GA: MAG Mutual Healthcare Solutions; 2010.
22. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422-5428.
23. Dial E, Fournier A, Moyneur E, Neary MP, Duh MS, Oh WK. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. Paper presented at: 2008 ASCO Annual Meeting; May 31-June 3, 2008; Chicago, IL.
24. Mickisch G, Escudier BJ, Gore ME, Walzer S, Sabaté E, Nuijten M. Cost of managing side effect in the treatment of fi rst-line metastatic renal cell carcinoma in Germany, France, and the UK: bevacizumab + interferon alpha-2a compared with sunitinib. Paper presented at: 2008 ASCO Annual Meeting; May 3-June 3, 2008; Chicago, IL.
25. Vanscoy GJ, Fortner B, Smith R, Weber R, Rihn TL. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Community Oncol. 2005;2(2):127-132.
26. Weiner MG, Ross SJ, Mathew JI, et al. Estimating the costs of chemotherapy-associated adverse event clusters. Health Serv Outcomes Res Methodol. 2007; 7(1):1-21.
27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Fort Washington, PA: NCCN; 2011:1-30.
28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Fort Washington, PA: NCCN; 2008:1-103.
29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain. Fort Washington, PA: NCCN; 2007: 1-19.
30. Beebe M, Dalton JA, Espronceda M. CPT 2009 Standard Edition. Chicago, IL: American Medical Association; 2008.
31. Physicians Desk Reference. Red Book 2010: Pharmacy's Fundamental Reference. Vol 113. Montvale, NJ: Thomson Reuters; 2010. 03